PROBLEM TO BE SOLVED: To provide new polymorphic and other crystalline forms of FTC, to provide a new method for preparing and isolating polymorphic and other crystalline forms of FTC and to provide a use of FTC polymorphic body, FTC of other phases and treatment purpose.SOLUTION: A solid phase of (-)-cis-FTC, which can be distinguished from form (I) (-)-cis-FTC by means of X-ray power diffraction pattern, thermal properties and methods of manufacture and is designated herein as amorphous (-)-FTC and (form II (-)-cis-FTC) and (form III (-)-cis FTC), is provided. Likewise, hydrated crystalline form of (±)-cis-FTC (that is, cis-FTC of racemic body) which can be distinguished from other forms of FTC by means of X-ray power diffraction pattern, thermal properties and methods of manufacture, and a dehydrated form of the hydrate are provided. These FTC forms can be used in the manufacture of other forms of FTC, or in pharmaceutical compositions. These forms are particularly desirably used for treating HIV or hepatitis B.COPYRIGHT: (C)2013,JPO&INPIT【解決手段】X線粉末回折パターン、熱特性、および製造の方法によってI型(-)-シス-FTCと区別することができ、ここでは非晶質(-)-FTCおよびIIおよびIII型(-)-シス-FTC)と呼ばれる(-)-シス-FTCの固相。同様にX線粉末回折パターン、熱特性、および製造の方法によって、FTCの他の型と区別することができる、(±)-シス-FTCの水和した結晶型(すなわちラセミ体のシス-FTC)、およびこの水和物の脱水された型。【効果】これらのFTC型は、他の型のFTCの製造、または薬剤組成物に使用できる。これらの型の特に好ましい使用は、HIVまたはB型肝炎の治療である。【選択図】なし
